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Summary
The generation of diradylglycerol (DRG) and phosphatidic acid (PdtOH) was investigated in
neutrophils primed with granulocyte-macrophage colony-stimulating factor (GM-CSF). Mass
accumulation of DRG and PdtOH was measured using reversed-phase high performance liquid
chromatography and thin layer chromatography, respectively. GM-CSF had no direct effect on
the levels of PdtOH and DRG, but it increased PdtOH generation and the late phase of DRG
accumulation in human neutrophils stimulated with FMLP. The elevation of the mass of PdtOH
peaked -100 s and clearly preceded that of DRG, which peaked at 150 s. The diacylglycerol
kinase inhibitor R59022 enhanced the sustained increase in DRG but did not produce a parallel
inhibition in PdtOH production. GM-CSF was without effect on the level of inositol 1,4,5-
triphosphate [Ins(1,4,5)P3] and did not affect the liberation of Ins(1,4,5)P3 induced by FMLP.
These findings exclude the involvement of the PtdIns(4,5)PZ-specific phospholipase C/diacylgly-
cerol pathway in the sustained phase of DRG accumulation. The early (30-s) appearance ofPdtOH
clearly suggests that GM-CSF enhanced FMLP receptor-linked phospholipase D (PLD) generation
of PdtOH. PLD was assessed more directly by formation of labeled phosphatidylethanol (PEt)
through PLD capacity of catalyzing a trans-phosphatidylation in presence ofethanol. The formation
ofPEt associated with a concomitant decrease in PdtOH directly demonstrated that the mechanism
by which GM-CSF enhances PdtOH production is activation of a PLD active on phosphatidyl-
choline. This study provides evidence that the mechanism ofaction ofGM-CSF involves upregulation
of PLD activity leading to enhanced generation of PdtOH and DRG in FMLP-stimulated
neutrophils. These findings may provide the basis for several of the priming effects of GM-CSF.
G
ranulocyte-macrophage CSF (GM-CSF)t, a glycopro-
tein of22 M is released by several cell types, including
T lymphocytes, fibroblasts, eosinophils, monocytes/macro-
phages, and neutrophils. Though GM-CSF has first been found
to promote the growth and the differentiation of myeloid
progenitors to both granulocytes and monocytes, it has also
been shown to influence the responsiveness ofmature human
phagocytes, in particular, neutrophils, to different stimuli (1-3).
Abbreviations used in this paper: DMF, dimethylformamide; DRG,
diradylglycerol; GM-CSF, granulocyte-macrophage CSF; HSA, human
serum albumin; LTB4, leukotriene B4; PdtOH, phosphatidic acid;
PEt, phosphatidylethanol; PKC, protein kinase C; PLC, phospholi-
pase C; PLD, phospholipase D; RT, room temperature.
Surface expression of functional antigens such as GFA1 and
GFA-2, as well as the adhesion molecules Mo-1 and Leu-M5
is increased by GM-CSF in the absence ofa subsequent stim-
ulation (4, 5). Preincubation of neutrophils with GM-CSF
is associatedwith a rapid increase in the number oflow affinity
FMLP receptors expressed on the cell surface (6), with a cyto-
solic alkalinization and a stimulation of membrane-bound
GTPase activity (7). GM-CSF-pretreated neutrophils show
enhanced responses to soluble stimuli, such as FMLP, leu-
kotriene B4 (LTB4), and platelet-activating factor (PAF). The
neutrophil responses shown to be augmented in GM-CSF-
treated cells include superoxide production (6), lysosomal en-
zyme release (4), calcium mobilization (8), and arachidonic
acid release and metabolism through the 5-lipoxygenase
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cytosis (11) and the concomitant synthesis of LTB4 (12).
Although high affinity binding sites for GM-CSF have been
demonstrated (13), little is known about the signal transduc-
tion pathway(s) involved in the actions ofGM-CSF. A growing
body of evidence implicates guanine nucleotide regulatory
proteins in coupling receptor occupancy to the activation of
the phospholipase C (PLC) pathway in neutrophils (14, 15).
PLC activation produces two putative second messengers, ino-
sitol 1,4,5-trisphosphate [Ins(1,4,5)P3], which releases Cat+
from intracellular stores, and diglycerides, which act as en-
dogenous activators of protein kinase C (PKC) (16) . Recent
data demonstrated the involvement of guanine binding pro-
teins in neutrophil activation and priming by GM-CSF (7,
17), as well as tyrosine phosphorylation ofproteins, including
the ras gene product P21 (2), a GTP binding protein. How-
ever, more recent reports dissociated the mechanism of action
ofGM-CSF from direct stimulation ofthe phosphatidylinositol
4,5-bisphosphate [Ptdlns(4,5)P2] hydrolysis pathway and
PKC activation (18, 19). On the other hand, it has been sug-
gested that GM-CSF may act through the modulation of the
generation of cyclic nucleotides (19).
Another potential signaling pathway in cell activation in-
volving a phospholipase D (PLD) has recently been studied
in various cell types, including human phagocytes and the
HIr60 human promyelocytic cell line (20-22). The activa-
tion of PLD may involve a guanine nucleotide binding pro-
tein (23) . It gives rise to choline-linked phosphoglycerides
breakdown products, namely choline and phosphatidic acid
(PdtOH), with diacyl-PdtOH and 1-0-alkyl-2-acyl-PdtOH
species (21, 22). PLD activation also leads to the formation
of the corresponding diradylglycerides (DRG) through a phos-
phatidate phosphohydrolase activity (24).
To gain insight into the mechanisms whereby GM-CSF
enhances neutrophil functional responsiveness, we have studied
its effects on the phospholipase pathway(s) involved in neu-
trophil activation. Our findings indicate that pretreatment
of the cells with GM-CSF leads to enhanced accumulation
of PdtOH and DRG upon simulation with FMLP, and
strongly suggest that this effect is mediated by an upregula-
tion of PLD activity.
Materials and Methods
Reagents.
￿
FMLP, 4-dimethylaminopyridine, triethylamine, PLD
(Cabbage type I), phosphatidylcholine (dioleoyl), phosphatidic acid
dipalmitoyl, 1,3-distearoyl-glycerol (1,3-distearin), 1,2-distearoyl-
rac-glycerol, 1,2-dipalmitoyl-sn-glycerol, 1.2-dioleoyl-sn-glycerol,
1-stearoyl-2-arachidonoyl-sn-glycerol, and coomassie brilliant blue
(CBB R-250) were purchased from SigmaChemical Co. (St. Louis,
MO). 1,2-dilinoleoyl-rac-glycerol was from Nu Check Prep Inc.,
(Elysian, MN). 1-0-hexadecyl-2-oleoyl- and 1-0-hexadecyl-2-
palmitoyl-sn-glycerol were prepared by PLC (type XIII; Sigma
Chemical Co.) digestion of the corresponding phosphatidylcho-
lines (Sigma Chemical Co.). 1-0-[3H]alkyl-2-acetyl-sn-glycero-3-
phosphocholine (132-179 Ci/mmol) was purchased from Amer-
sham Corp. (Arlington Heights, IL). a-naphthyl-isocyanate and
1,8-diazacyclo-[5,4,0]-undec-7-ene were from Aldrich Chemical Co.
(Milwaukee, WI). Dimethylformamide was from Pierce Chemical
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Co. (Rockford, IL). Silica gel 60 thin layerchromatography (TLC)
plates were from Merck & Co. (Darmstadt, FRG). R59022 was
bought from Janssen Life Sciences (NJ). HBSS was from Gibco
Laboratories (Burlington, Ontario), and all solvents were HPLC
grade from Anachemia (Montr6al, Qu6bec). Biosynthetic human
recombinant GM-CSF (The Genetics Institute, Cambridge, MA)
was resuspended in sterilebuffered saline containing 0.01% human
serum albumin (HSA); its stock solution (at 100 nM) was stored
at -20°C and handled aseptically.
NeutrophilPreparation.
￿
Neutrophil suspensions were prepared
as previouslydescribed (25). Briefly, venous blood collected on ci-
trate dextrose phosphate adenineanticoagulant solution from healthy
volunteers was centrifuged (250 g, 10 min), and the platelet-rich
plasma was discarded. After dextran sedimentation, PMN were ob-
tainedby centrifugation over a Ficoll-Paque cushion. Contaminating
erythrocytes were removed by hypotonic lysis, and purified neutro-
phils (98% neutrophils) were finally resuspended in HBSS con-
taining 10 mM Hepes and 1.6 mM Cal*, pH 7.4. Cells were
counted (model ZM; Coulter Electronics Inc., Hialeah, FL) and
diluted in HBSS to a final concentration of 2 x 10'/ml. Cell via-
bility, as determined by trypan blue dye exclusion, was always >96%
at the end of each experiment.
Incubation Conditions.
￿
Neutrophils (2 x 10'/ml) were prein-
cubated at room temperature (RT; 20°C) for the desired period
of time with or without 400pM GM-CSF (a concentration ofGM-
CSF previouslydescribed to induce optimal priming effects on neu-
trophil functions; see references 8 and 12). The cell suspensions
were then warmed to 37°C for 5 min before FMLP challenge. At
selected times after the addition ofFMLP, the reactions were stopped
by vortexing 4-ml aliquots of neutrophil suspensions with 7.2 ml
of ice-cold chloroform/methanol/HCI (10 N) (100:200:2; vol/
vol/vol). Control experiments used unstimulated neutrophils prein-
cubated with or without GM-CSF. In the experiments with the
DRG kinase inhibitor R59022, neutrophils were preincubated 10
min at 37°C with 20 p.M R59022 before the addition of FMLP,
as described (26).
Sample Preparation for DRG and PdtOH Analysis.
￿
Lipids were
extracted by the Bligh and Dyer's technique (27), with modification.
Briefly, after vortexing the cell suspension with cold chloro-
form/methanol/HCI (10 N) (as described above), samples were
mixed with chloroform (0.6 ml/ml of the original cell solution)
containing 1 lAg of 1,3-distearin as an internal standard. After cen-
trifugation (750 g, 10 min at 4°C), the chloroform layerwas care-
fullyremoved, and the aqueous layerwas vortexed with 2 ml chlo-
roform. The combined chloroform fractions were washed with 1 ml
of 0.1 N HCI and dried under nitrogen. The lipid samples were
then dissolved in chloroform/methanol (1:2; vol/vol).
TLC ofLipids.
￿
Separation of the different neutral lipids was
achieved using silica gel-60 plates previously developed in chloro-
form/methanol (1:2; vol/vol) for cleaning purposes. The elution
solvent was made up ofbenzene/chloroform/methanol (80:15:3.25;
vol/vol/vol) (system I). After evaporation of organic solvents under
nitrogen, the plates were slightly stained with coomassie brilliant
blue. Theplates were then dried, the areas containing the diglycer-
ide subclasses were scraped off, and the silica gel was collected.
The DRG were eluted from the silica gel with 8 ml hexane/ether
(25:75; vol/vol). The samples were dried under nitrogen, and the
DRG were either converted to their naphthylurethane derivatives
for subsequent separation and quantitation by HPLC (see below)
or to their anthracene-propionyl derivatives for further analysis by
mass spectrometry (see below).
PdtOH were resolved from other lipids by TLC on silica gel-60
using a solvent containing chloroform/pyridine/88% formic acid
Priming Effects of Granulocyte-Macrophage Colony-Stimulating Factor(50:30:7; vol/vol/vol) (system II). In some experiments, after an
initial development of the TLC plate in system I, the phospho-
lipids that remain at the origin were scraped offandrecoveredfrom
the silica gelby sequential elution with 5 ml chloroform/MeOH
(1:2; vol/vol) and2ml McOH, and separatedusingsolvent system
II to resolve PdtOH.
Analysis ofDRG: HPLC Separation andQuandtadon ofDRG. DRG
samples purified by TLCwith solvent system I andrecovered from
TLC plates were prepared for analysis using a slight modification
of Rustow's method to obtain naphthylurethane derivatives (28).
Briefly, dried DRG samples were dissolved in 100 pl dimethylfor-
mamide (DMF). 5 Pl of a-naphthylisocyanate (a large excess of
the reagent) and 10 pl of 1,8-diazacyclo-[5,4,0]-undec-7-ene (0.1
M solution in DMF) were added simultaneously to each sample.
The stoppered glass vials were heated at 85°C under nitrogen for
30 min. Aftercoolingto RT, excess reagentwas destroyedby addi-
tion of 500 14 of McOH for 10 min, and the reaction mixture
was then centrifuged (250 g, 5 min at RT). The clear supernatant
was carefully removed, and the precipitated material was then
resuspended in 0.6 ml ether and centrifuged at 250 g. The clear
supernatants were combined and mixed with 10 ml of solvent A
(acetonitrile/water, 75:25; vol/vol) and applied to Sep Pak Cis car-
tridges (Waters Associates, Milford, MA) prewashed with 15 ml
solvent A. The samples were then washed with 5 ml solvent A,
followed by 10 ml acetonitrile/water (90:10), and the derivatized
DRG were eluted with 5 ml of distilled n-hexane. Thederivatized
DRG samples were dried anddissolved in isopropanol for HPLC
analysis. SepPakcartridges were then washed with 4ml isopropanol
and reequilibrated with solvent A for further use. Separation and
quantitation of neutrophil DRG was achieved using a Radial Pak
Cs cartridge (5 x 100 mm, 10-um particles; Waters Associates)
protected by a Cs guard cartridge (Pierce Chemical Co.). Deriva-
tized DRG were eluted at a flow rate of 1.5 ml/min using two
solvent mixtures: solvent A-1, acetonitrile/water (70:30; vol/vol)
and solvent A-2 (100% acetonitrile), and the following program:
step 1, 0-5 min, isocratic in A-1; step 2, 5-5.5 min, 100% A-1
to 33% A-1/67% A-2; step 3, 5.5-11.5 min isocratic in 33% A-I/
67% A-2; step 4, 11.5-13 min from 33% A-1/67%D A2 to 5%
A-1/95% A-2; step 5, 13-16 min, isocratic in 5% A-1/95% A-2;
step 6, 16-16.1 min from 5% A-1/95% A-2 to 100% A-2; step
7, 16.1-26 min, isocratic in 100% A-2; step 8, 26-26.1 min from
100%D A-2 to 100% A-1; step 9, 26.1-36.5 min isocratic in 100%
A1. DRG species were detected by absorbance at 223 nm using
avariable wavelength UV photometer. Theproducts were identified
on thebasisof theircoelutionwith authenticstandards. Quantita-
tion of DRGwas performedby comparison of thepeak areas with
that of theinternal standard 1,3-distearin; quantitative values given
forDRGare the sum of all DRG species appearing on the HPLC
tracings. Those conditions of analysis using UV detection at 223
nm allowed a detection limit of 5-10 pmol DRG.
Analysis ofPWOH.
￿
Samplesprepared forPdtOH analysis (using
TLCwith solvent system II, seeabove) were stainedwith coomassie
brilliant blue, as described by Nakamura and Handa (29). Briefly,
TLCplates were immersed in a 0.03% solution of thedyein 30%
McOH containing 100 mM NaCl, for 30 min, and destained for
5 min in 30% McOH, 100 mM NaCl. The plates were air dried
and scanned using an image analysis system (Amersham Corp.).
Integration of thin layer bands wasperformedusing GIA000 soft-
ware supplied with theimageanalyzer (AmershamCorp.). Quan-
titation of PdtOHwas achieved using a standard curve (0.75, 1.5,
and314g)dipalmitoyl phosphatidate obtained for each analysis. In
some experiments, the fatty acid composition of TLC-purified
PdtOHwasstudiedby GC-MSusingtheproceduredescribedabove
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forDRG species. Alkyl-PdtOHwereassessed as alkyl-lyso-PdtOH
after alkaline hydrolysis of TLC-purified PdtOH species. Briefly,
PdtOH were hydrolyzed with 80% methanolic NaOH (1 N) over-
night at RT, andthebase hydrolysis products were extractedusing
the Bligh and Dyer's technique (27). Theorganic phasewas then
driedandanalyzedon silica gelusingsolvent system II.Lyso-alkyl-
PdtOHwere quantitated usingcharring densitometry (30) andlyso-
PdtOH for standard curve.
Preparation ofPhosphatidylethanol (PEt).
￿
PEtwasprepared from
phosphatidylcholine (dioleoyl) by trans-phosphatidylation with cab-
bage PLD. CabbagePLD(50 U) dissolvedin 1ml of 10% ethanol,
40 mM calcium chloride, pH 5.6, and400wg ofphosphatidylcho-
line dissolved in 1 ml ofwater-saturateddiethylether were incubated
overnight at RT. Thelipids were extractedwith diethylether/eth-
anol (4:1;vol/vol), andtheorganicphasewasdriedundernitrogen
before being separated by TLC on silica gel-60 plates in chloro-
form/methanol/acetic acid (65:15:2;vol/vol/vol) (21).PEt was local-
ized by coomassiebrilliantblue staining (29) andidentifiedby com-
parison to published Rf values (21).
PEt Biosynthesis in Neutrophils.
￿
Neutrophils (10) were prela-
beled with 1-0-['H]alkyl-2-acetyl-sn-glycero-3-phosphocholine.
1-0-['H]alkyl-2-acetyl-sn-glycero-3-phosphocholine (10 PCi/ml, in
HBSS containing 2.5 mg HSA was added to the cell suspension
at thefinalconcentration of15 nM (2 uCi/ml), and the cellswere
incubated at 37°C for 90 min. Cells were washed twicein HBSS
buffer containing 0.5 mg/ml HSA and resuspended in the same
buffer (without HSA) to a final concentration of 10'/ml. Cells
were treatedwith 400pM GM-CSF or diluent, as describedabove.
The cell suspensions were then warmed to 37°C for 5 minbefore
FMLP challengein the absenceor presence of 0.5% ethanol added
1 min before theagonist. Lipids were extracted as described above
and the lipids were resolved by TLC on silica gel-60 plates as be-
fore. Standard lipids were located by coomassiebrilliantblue staining
andplates were scraped in 5-mm slices andassayed forradioactivity.
Inositol 1,4,STrisphosphate (Ins(1,4,5)P3) Measurement by RIA.
￿
Ins-
(1,4,5)P3was assayed in incubation media with a commercial RIA
kit (Amersham Corp.). Briefly, neutrophils (10'/ml) were prein-
cubated for 1 h at 37°C with or without 400 pM GM-CSF before
stimulation with 1 pM FMLP. Incubations were terminated by
addition of 1 vol ice-cold TCA (15%). After sedimentation of
precipitated material, supernatants were extracted with 10 vol of
water-saturated diethyl ether and then titrated to pH 7.5 with
NaHC03. The amounts of Ins(1,4,5)P3 in neutralized superna-
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Reverse-phase HPLC
elution profile of naphthylure-
thane derivatives of standard di-
glycerides. Standard DRG were
converted to their naphthylure-
thane derivatives, purified and
separated by RP-HPLC, as de-
scribed in Materials and Me-
thods. 20-300 pmol of each
DRG standard was applied on
the column: A, 1,2-diacyl
Cis:a/Cts:z; B, 1,2-diacyl Cis:o/
Cz0:4; C, 1,2-diacyl Cis:t/Cisa;
D, 1-0-alkyl-2-acyl C16:0/C16:0;
E, 1-0-alkyl-2-aryl C1s:o/C3sA; F,
1,2-&aryl Cis:o/Cls:o (arises from
isomerization of the 1,3-&aryl
C1m/Cmo standard [peak G]).tants were assessed using Amersham Corp.'s specified assay
procedures.
Statistical Analysis.
￿
Results are expressed as the mean ± SEM
of at least five experiments. Statistical analysis was performed by
student's paired t test, and significance was consideredattained when
p was <0.05, one-tailed.
Results
Influence of GM-CSF on DRG Levels in Human Neutro-
phils. Separation and quantitation of human neutrophils
DRG were performed using a sensitive HPLC-UV method
that did not require radiolabeling. Standards of various DRG
species were separated as naphthylurethane derivatives by
HPLC (Fig. 1). The elution times of DRG naphthylurethane
derivative standards were dependent on the degree of fatty
acid unsaturation and carbon chain length. The 1,2-diaryl
(C18:2/C18:2 derivative eluted first (Fig. 1, peak A) and was
followed by 1,2-diaryl C18:0/C20:4 (peak B), 1,2-diaryl
C18:1/C1m (peak C), 1-0-alkyl-2-aryl C1s:0/C16:o (peak D),
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1-0-alkyl-2-aryl C16:o/C1aa (peak E), 1,2-diaryl C18 :0/C18 :0
(peak F), and 1,3-diaryl C1a:o/C18:o (peak G). Using this
HPLC system, naphthylurethane derivatives ofDRG obtained
from neutrophils eluted between 17 and 25 min of the 36.5-
min elution program (Fig. 2). The limit ofdetection for DRG
naphthylurethanes, as assessed with 1,2-dioleoylglycerol at 223
nm, was 5-10 pmol. The identification ofpeaksin biological
sample chromatograms was made by comparison of reten-
tion times with those of DRG standards. We used 1,3-distearin
as an internal standard to monitor DRG recovery throughout
the extraction procedures and conversion into naphthylurethane
derivatives. The 1,3-distearin naphthylurethane standard eluted
as two peaks (Fig. 1, peaks F and G; Fig. 2, peaks 8 and
9). In fact, TLC analysis of the commercial 1,3-distearin stan-
dard revealed the presence ofthe 1,2-distearin isomer, which
eluted as peak F ofFig. 1 in HPLC analysis. In contrast, we
did not observe the presence of 1,3-DRG isomers in TLC
analysis ofbiological DRG samples. Recovery of the internal
standard at the level ofHPLC analysis was found to be 30-50%.
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Figure 2.
￿
Reverse-phase HPLC
elution profiles of naphthylurethane
derivatives of endogenous DRG
from normal human blood neutro-
phils. Neutrophils (2 x 107/ml)
were preincubated for 1 h at RT
without GM-CSF (A and B) or in
presence of 400 pM GM-CSF (C
and D) before stimulation with
1 pM FMLP for 2.5 min at 37°C
(B and D). The DRG from 5 x
107 cells were separated by TLC on
Silica gel using solvent system (1),
converted to their naphthylurethane
derivatives and separated by RP-
HPLC, as described in Materials and
Methods. Peaks were identified by
comparison of their elution times
with those of derivatized standards
(see Fig. 1). Peak 1 corresponded to
1,2-diaryl Cis:z/Cis:a standard; peaks
2 and 3 were not identified; peaks
4-9 corresponded to 1,2-diaryl
Cie:o/CZO:a, 1,2-diacyl Cis:1/Cisa,
1-0-alkyl-2-aryl C1e:o/Gs:o, 1-0-
alkyl-2-aryl C1c:o/C1sa, 1,2-diaryl
Ge:o/Ge:o, and 1,3-diaryl Ws:o/
Cis:o, respectively. Chromatograms
A, B, C, and D are derived from
one representative experiment (cells
were from the same donor); this ex-
periment was repeated five times
with similar results.J
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Effect of GM-CSF on the time course of DRG produc-
tion in human neutrophils stimulated by FMLP. Neutrophils were
preincubated at RT for 1 h with or without 400 pM or GM-CSF
before stimulation with 1 KM FMLP for 2.5 min at 37°C. The en-
dogenous DRG were purified and derivatized into naphthylurethane
derivatives before RPHPLC, as described in Materials and Methods.
The amount of the DRG species formed at each time point was mea-
sured and the total amount was calculated. The results show the
mean ± SEM of five experiments. The asterisks indicate that p <
0.05. The control values obtained at 0 min in unstimulated neutro-
phils were used to calculate the percentage and the p values shown.
HPLC analysis ofDRG species also showed some qualitative
limitations; for example, compounds C18:0/C20:4 (Fig. 1, peak
B) and Ctb:0/Ci6:0 were found to have identical retention
times in the system used.
sn-DRG Level in Neutrophib. Human neutrophils, in-
cubated with or without 400 pM GM-CSF for 1 h at RT,
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Figure 4.
￿
Effect of GM-CSF on the time course of Ins(1,4,5)P3
production in FMLP-stimulated human neutrophils. Neutrophils
(107/ml) were preincubated with or without 400 pM GM-CSF for
1 h at RT before stimulation with 1 AM FMLP at 37°C. Ins(1,4,5)P3
levels were measured by RIA after extraction, as described in
Materials and Methods. The results are expressed as the mean ±
SEM of five experiments.
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showed similar levels of DRG (sum of all species detected),
e.g., 167 ± 36 and 159 ± 29 pmol/101 neutrophils, respec-
tively (n = 5), as assessed by HPLC analysis and correction
for recovery using the internal standard. Similarly, we did
not detect changes in the basal levels of DRG upon incuba-
tion of the cells with GM-CSF, over a 30-min period at 37°C'
(data not shown). These data indicated that GM-CSF did
not induce by itself the formation of DRG.
Fig. 3 shows the kinetics of the changes in DRG levels
in FMLP-stimulated neutrophils. When neutrophils were
stimulated with 1 AM FMLP, the levels of DRG rapidly in-
creased by 45% within 30 s (p < 0.05), then dropped back
to basal levels by 2.5 min. This was followed by a slower
rise of DRG at 5 min (final level, 141% of basal). Neutro-
phils treated with GM-CSF exhibited two phases of DRG
accumulation when challenged with FMLP (Fig. 3). The most
striking effect of GM-CSF pretreatment was a second phase
of DRG accumulation, which was maximal at 2.5 min be-
fore dropping back to basal levels by 5 min (Figs. 2 D and
3). The mean change (percent ofcontrol) of that second peak
was 208 ± 26% (p < 0.05), ranging from 135 to 293%.
The first peak ofDRG accumulation in GM-CSF-treated neu-
trophils stimulated with FMLP reached 153% (p < 0.05) of
the basal DRG levels. While there was no difference in the
level ofthe first peak (30 s) ofDRG accumulation in control
or GM-CSF-treated cells, the levels of DRG at 2.5 min were
significantly elevated in cellspre-exposed to the growth factor
as compared with control cells.
Effect ofGM-CSF on Ins(1,4,5)P3 Formation in Human Neu-
rophih. The binding of FMLP to its receptor in neutrophils
leads to phospholipase C-induced hydrolysis of phosphati-
dylinositol 4,5-bisphosphate (Ptdlns(4,5)P2) (31). We exam-
ined the effect of GM-CSF on the formation of Ins(1,4,5)P3,
a breakdown product of PtdIns(4,5)P2 hydrolysis. Basal levels
of Ins(1,4,5)P3 in unstimulated neutrophils were unchanged
by GM-CSF treatment. Neutrophil stimulation with FMLP
was associated with a rapid (30 s) and transient production
of Ins(1,4,5)P3 (Fig. 4); Ins(1,4,5)P3 levels increased from a
mean baseline of 2.2 ± 0.3 pmol/107 cells to a mean max-
imal level of 4.5 ± 1.0 pmol/10' cells. Neither the time
course nor the maximal production of Ins(1,4,5)P3 in FMLP-
stimulated neutrophils were altered by GM-CSF treatment.
Under those conditions, GM-CSF treatment increased the
FMLP-induced 02' production by 170 ± 12% (n = 3). It
is noteworthy that the kinetics of accumulation of Ins(1,4,
5)P3 and DRG in neutrophils stimulated with FMLP (Figs.
3 and 5) were very similar.
InfluenceofGM-CSF on theLevels ofPdtOHin HumanNeu-
trophils. The stimulation of neutrophils by FMLP led to a
slight but nonsignificant increase ofthe level of PdtOH within
1 min 45 s (Fig. 5). GM-CSF, by itself, did not affect the
basal levels of PdtOH in unstimulated neutrophils (data not
shown). However, the addition ofFMLP to GM-CSF-treated
neutrophils resulted in a rapid and significant increase of the
levels of PdtOH, which was detectable as early as 30 s and
remained stable for up to 5 min (Fig. 5). Under these condi-
tions, PdtOH increased from 0.24 ± 0.07 Fig to 0.99 ± 0.15Table 1.
￿
Changes in Dglyceride Subspecies as a Function of
Time in GM-CSF-treated Neutrophils Stimulated with FMLP
Peak 0
To calculate changes in diglyceride subspecies, an arbitrary unit of 1
was given to each subspecies (control at 0 min). Data represent the
mean ± SEM of five experiments.
"p < 0.05.
wg/107 neutrophils at 1 min 45 s. At each time studied after
FMLP challenge, the levels of PdtOH in GM-CSF-treated
neutrophils were consistently two- to threefold higher than
those of cells that had prior stimulation with FMLP (t =
0 min; Fig. 5).
Preincubation of GM-CSF-treated neutrophils with
R59022, a DRG kinase inhibitor, was associated with a
significant enhancement ofboth phases of FMLP-induced ac-
cumulation of DRG (Fig. 6). In contrast, preincubation of
neutrophils with 20 j,M R59022 did not significantly alter
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Time course of the formation of Pdt0H in FMLP-
stimulated neutrophils. Neutrophils (2 x 107/ml) were preincubated
with or without 400 pM GM-CSF for 1 h at RT before stimulation
with 1 p.M FMLP at 37°C. PdtOH from 3.5 x 107 cells were sepa-
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coomassie brilliant blue staining, as described in Materials and
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to J
W
W
J w ~-
J
Id GC r-v
￿
300 -
ut o
U
>
450
400-
350-
250-
CONTROL
A- R59022
772
￿
Priming Effects of Granulocyte-Macrophage Colony-Stimulating Factor
0 1.0 2.0 3.0 4.0 5.0
TIME (min)
Figure 6.
￿
Effect of R59022 on the time course of the production
of DRG in GM-CSF-treated neutrophils. Neutrophils were prein-
cubated with 400 pM GM-CSF for 1 h at RT and incubated 10 min
with or without 20 AM R59022 at 37°C before stimulation with
1 uM FMLP at 37°C. Endogenous DRG from 8 x 107 cells were
purified by TLC, derivatized before RP-HPLC analysis, as described
in Materials and Methods. DRG were calculated as described in the
Fig. 3 legend. Results show the mean ± SEM of five experiments.
The asterisks indicate that p < 0.05.
the time course ofaccumulation of PdtOH in GM-CSF-treated
neutrophils stimulated with FMLP (Fig. 7). Basal levels of
DRG andPdtOH in unstimulated neutrophils pretreated with
GM-CSF were unchanged by preincubation of cells with
R59022. Taken together, these observations are consistent
with a major contribution of a PLD in the generation of
PdtOH induced by GM-CSF treatment.
The alkyl-acyl composition of PdtOH was studied after
basic hydrolysis under mild conditions (80% methanolic 1 N
NaOH; 15 h at RT). The resulting products were extracted
and purified by TLC. The levels of alkyl-PdtOH were not
detectable in control cells nor in unstimulated cells treated
with GM-CSF using charring densitometry (results not
shown). However, when GM-CSF-treated neutrophils were
stimulated with FMLP, alkyl-PdtOH rapidly increased to a
detectable level and reached a plateau (0.06 ,ug/107 neutro-
phils) corresponding to 5-10% of the total PdtOH content
within 60 s (Fig. 8) . However, since recovery of a standard
was not included, the values may underestimate the amount
of alkyl-PdtOH.
Effect ofGM-CSF on PEt Formation in Human Neutrophils.
Advantage was taken of property of PLD-catalyzed formation
of PEt by transphosphatidylation reaction in the presence of
ethanol to assess the effect ofGM-CSF on PLD activity. When
1-0-[3H]alkyl-2-acetyl-sn-glycero-3-phosphocholine was added
for 90 min to human neutrophils, 85 ± 2% was taken up
by the cells. 88 ± 2% (n - 3) of the totalcell radioactivity
was in alkyl-acyl-phosphatidylcholine. Stimulation of these
prelabeled neutrophils with FMLP led to a production of
[3H]alkyl-PdtOH. The level of [3H]alkyl-PdtOH peaked
within 1 min (two- to threefold) and declined slowly there-
after (data not shown). The most striking effect ofGM-CSF
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Figure 7.
￿
Effect of 859022 on the time course of the production
of Pdt0H in GM-CSF-treated neutrophils. Neutrophils were prein-
cubated with or without 400 pM GM-CSF for 1 h at RT and in-
cubated 10 min with 20 AM R59022 at 37°C before stimulation
with 1 jAM FMLP at 37°C. PdtOH from 3.5 x 107 neutrophils
were purified by TLC and quantified by densitometry after coomassie
brilliant blue staining, as described in Materials and Methods. Data
represent the mean t SEM of four experiments.
pretreatment was an accumulation of [3H]alkyl-PdtOH in
FMLRstimulated neutrophils (Fig. 9). Addition of 0.5% eth-
anol to control or GM-CSF-treated neutrophils 1 min before
FMLP challenge led to a 50-60% inhibition of [3H]alkyl-
PdtOH accumulation. Inhibition of [3H]alkyl-PdtOH for-
mation was correlated with the formation of a novel [3H]-
labeled product (Rf = 0.5) with Rfsimilar to the standard
PEt. Formation of this product, identified as [3H]alkyl-PEt
(21), was increased 2.4-fold in neutrophils pretreated with
GM-CSF (Fig. 9). These data demonstrate that GM-CSF up-
1 .0 2.0 3.0 4.0 5.0
Figure 8.
￿
Time course production of alkyl-PdtOH in GM-CSF-
pretreated neutrophils. PdtOH from 1.8 x 108 neutrophils treated for
1 h at RT with 400 pM GM-CSF and stimulated with 1 pM FMLP
at 37°C was submitted to base hydrolysis. Base hydrolysis products
were extracted and separated by TLC. Alkyl-lyso-PdtOH were quanti-
tated by charring densitometry using a standard curve obtained with
lyso-PdtOH. Data are the mean t SD of two separate experiments.
* GM-CSF + fMLP
o GM-CSF + fMLP + 0.5% Et
* fMLP
o fMLP + 0.5% Et
PdtOH
Figure 9.
￿
Formation of Pdt0H and PEt in human neutrophils.
Human neutrophils were labeled with 1-0-[3H]alkyl-2-acetyl-sn-
glycero-3-phosphocholine, as described in Materials and Methods.
Cells (107/ml) were pretreated with or without GM-CSF (400 pM)
for 1 h at RT before stimulation with 1 AM FMLP at 37°C in the
presence or absence of 0.5% ethanol. Lipids were extracted and sepa-
rated by TLC, and standard lipids were located by coomassie brilliant
blue staining. Plates were scraped in 5-mm slices and assayed for ra-
dioactivity. Shown is a single experiment representative of three
different ones.
regulates a phosphatidylcholine-specific PLD under these con-
ditions.
Analysis ofDRG Species in Neutrophib.
￿
Besides providing
a mean for quantitation of DRG, HPLC also enabled com-
parison ofthe various DRG species formed under the different
experimental conditions tested. HPLC analysis of the DRG
in control neutrophils showed four principal DRG peaks(Fig.
2 A ; peaks 4, S, 6, and 7). Peak 4 coeluted with C18:o/C2o:4
and C16:0/C16:o AAG standards (Fig. 1, peak B). Peaks 5, 6,
and 7 comigrated with diacyl C18a/C1m, 1-0-alkyl-2-acyl
C16:0/Ct6:o, and 1-0-alkyl-2-acy1 C16:o/C18:1 DRG standards,
respectively (Fig. 1, peaks C, D, and E). The DRG species
eluting as peaks 2 and 3 have not yet been identified. Peak
1 had a retention time identical to that of C18:2/C18:2 (Fig.
1, peak A) . The profile of DRG species in neutrophils was
unchanged by preincubation with GM-CSF (Fig. 2 C). Simi-
larly, we did not detect significant changes in the profile of
DRG after a 2.5-min stimulation with FMLP (Fig. 2 B). In
contrast, cells treated with GM-CSF exhibited major changes
in several DRG species after 2.5-min stimulation with FMLP,
with a significant increase of peaks 1,
,3,
and 4 (Fig. 2 D).
Peak 4 showed the highest enhancement, averaging 307 ±
89% (n = 5) of its basal level. Peak 1, which eluted just
after a contaminant, was detected only in GM-CSF-pretreated
neutrophils stimulated with FMLP. As function of time,
changes in DRG levels were due to a major contribution of
peaks 1, 3, and 4.Discussion
In the present study, we investigated the effects of GM-
CSF on DRG and PdtOH levels in resting and stimulated
neutrophils. It is important to point out that the present in-
vestigation relied on mass measurements, in contrast to
previous studies on DRG and PdtOH in human neutrophils,
which were carried out with cells prelabeled with radioiso-
topes (22, 31). It is indeed uncertain that true isotopic equi-
librium of membrane lipids was reached by the short periods
ofradiolabeling used in those studies (32). Therefore, it seems
that direct mass measurement is likely to provide a more reli-
able determination of the changes in lipid species.
We demonstrated herein that in human neutrophils pre-
treated with GM-CSF, the chemotactic peptide FMLP in-
duced a rapid accumulation of PdtOH, and secondarily of
DRG. GM-CSF treatment had no direct effect on the levels
of DRG, PdtOH, and Ins(1,4,5)P3 in unstimulated neutro-
phils, and affected neither the FMLP-stimulated formation
of Ins(1,4,5)P3 nor the initial peak of DRG accumulation.
Activation of neutrophils by chemoattractants is depen-
dent upon GTP-binding proteins coupled to a PLC specific
for Ptdlns(4,5,)P2 (33). Hydrolysis of Ptdlns(4,5)P2 leads
to a transient rise in Ins(1,4,5)P3 and a biphasic increase in
diacylglycerol (34-36). The second phase of DRG increase
observed in cytochalasin B-pretreated neutrophils stimulated
with FMLP is correlated with optimal activation of the re-
spiratory burst (35), and unlike the initial increase, was ap-
parently derived from a phospholipid other than PtdIns
(4,5)P2 (36). Our findings clearly ruled out a PtdIns(4,5)P2-
specific PLC/diacylglycerol pathway in the mechanism ofGM-
CSF action, since the concomitant early peaks in Ins(1,4,5)P3
and DRG were not alteredby the cytokine in FMLP-stimulated
neutrophils. Using [3H]inositol-labeled neutrophils, Coffey
et al. (19) reported similar results. Several lines of evidence
also dissociate the late increase in DRG from the PtdIns
(4,5)P2-specific PLC pathway in cells treated with GM-CSF,
and it has been suggested that DRG can be generated by PLC
hydrolysis of a phospholipid other than Ptdlns(4,5)P2 or by
another pathway (22, 31). Indeed, both PMA and dioctanoyl-
glycerol induced the accumulation of DRG (1-0-alkyl-2-
acylglycerol [EAG] and 1-2-diacylglycerol [AAG]) in human
neutrophils without phosphoinositide hydrolysis and calcium
mobilization (36-39). In several cell types, the PMAstimulated
release ofDRG and choline metabolites was consistent with
the PLC-mediated hydrolysis ofphosphatidylcholine (40, 41) .
Recent evidence has implicated a PLD in the formation
of PdtOH in chemoattractant-stimulated H1s60 cells and
neutrophils (20-22, 31). Stimulation of 1-0-alkyl-[32P]-PC-
labeled cells with FMLP or PMA was found to induce the
generation of alkyl-PdtOH from alkyl-phosphatidylcholine,
most likely through a PLD activity (21). In addition, the
recent demonstration of DRG formation with concomitant
phosphorylcholine turnover in humanPMN is consistent with
an activation of a PLD activity (42).
In GM-CSF-treated cells stimulated with FMLP, a three-
fold increase in PdtOH preceded the twofold increase in DRG
(Figs. 2, 3, and 5) . Under these conditions, the mass of PdtOH
774
was consistently four- to fivefold higher than the mass of DRG.
Although PdtOH accumulation preceded the sustained phase
ofDRG formation in GM-CSF-treated neutrophils challenged
with FMLP, it remains possible that PdtOH could be de-
rived from a rapidphosphorylation of the DRG pool. If so,
PdtOH accumulation should havebeen inhibited by the DRG
kinase inhibitor R59022 (43). We found that R59022 in-
creased thelate phase ofDRG accumulation, but was without
significant effect on the time course of formation and accumu-
lation of PdtOH. These observations indicated that most of
the PdtOH pool is generated through the activation ofa PLD.
In addition, our findings of an increased proportion of base-
stable PdtOH, identifiedas alkyl-PdtOH, in GM-CSF-treated
neutrophils challenged with FMLP suggest that, since neu-
trophils do not contain alkyl-PtdIns(4,5)P2, a phosphatid-
ylcholine-specific PLD might be activated under these con-
ditions.
It has recently been suggested, on the basis of PdtOH ac-
cumulation and inhibition of AAG formation by propanolol,
an inhibitor of phosphatidate phosphohydrolase, that DRG
were formed by sequential action of PLD and PdtOH phos-
phohydrolase in FMLPstimulated neutrophils pretreated with
cytochalasin B (31). Moreover, the observed accumulation of
either alkyl-PdtOH and alkyl-DRG provided additional evi-
dence that PdtOH and DRG are generated by hydrolysis of
phosphatidylcholine by a PLD (22, 31). We have found in
GM-CSF-treated neutrophils that 100 1AM propanolol increased
the basal level of PdtOH from 0.109 ± 0.026 to 0.244 t
0.07 Wg/10' neutrophils. In GM-CSF-treated neutrophils
stimulated with FMLP for 2.5 min, propanololincreased the
levels of PdtOH from 0.388 ` +_ 0.054 to 0.483 ± 0.058
feg/10' cells. These efdc¬sofpropanolol provide evidence for
the presence of an -active phosphatidate phosphohydrolase,
and indicate that part ofthe DRG accumulation itsGM-CSF-
treated' neutrophils stimulated with FMLP may derive from
PdtOH via a phosphohydrolase. However, our results do not
exclude DRG formation by a phospholipase C-mediated hy-
drolysis of phosphatidylcholine (40, 41) .
Stimulation by FMLP of 1-0-[3H]alkyl-2acyl-sn-glycero-
3-phosphocholine-prelabeled neutrophils, led to rapid and
enhanced formation of [3H]alkyl-PdtOH in GM-CSF-pre-
treated neutrophils. In addition, in the presence of ethanol,
an increased formation of [3H]alkyl-PEt (concomitant with
a decreased generation of [3H]alkyl-PdtOH) was observed in
GM-CSF-pretreated neutrophils challenged with FMLP. As
PLD catalyzes trans-phosphatidylation in presence ofalcohols
(21), we concluded that GM-CSF upregulates a phospha-
tidylcholine-specific PLD in FMLP-stimulated neutrophils.
The RP-HPLC analysis of naphthylurethane derivative of
neutrophil DRG, in addition to providing quantitative data,
also unravelled specific alterations in the DRG profiles of neu-
trophils under various experimental conditions. Identification
of the various DRG species, based on coelution with authentic
standards is tentative and requires confirmation. Preliminary
mass spectrometric analysis (datanot shown) already confirmed
that neutrophil DRG contain all the species detected by HPLC
(and several others) and, furthermore, confirmed the major
Priming Effects of Granulocyte-Macrophage Colony-Stimulating Factorchange observed in DRG species after FMLP stimulation of
GM-CSF-treated neutrophils (Fig. 2), i.e., an increase mainly
in C18:o/C2o:4 AAG. Studies are currently in progress to char-
acterize DRG and PdtOH profiles in resting and activated
neutrophils. Such analysis of DRG and PdtOH species are
crucial to the understanding of the regulation of the pools
of precursors of bioactive lipids, such as arachidonic acid
(44-46), and of cellular responses, since AAG and EAG spe-
cies have different regulatory properties on PKC activity and
superoxide production (47).
It is noteworthy that there are several similarities between
the effects of.GM-CSF and the fungal metabolite cytochalasin
B. We have found that neutrophil pretreatment with
cytochalasin B or GM-CSF similarly enhanced the accumu-
lation of DRG upon stimulation with FMLP (see also refer-
ence 31), and that cytochalasin B treatment ofGM-CSF primed
neutrophils did not cause a cumulativeincrease of DRG (data
not shown) . Like GM-CSF, cytochalasin B primes neutro-
phils for enhanced functional responses, including degranu-
lation (48), respiratory burst (35), and phospholipase A2 ac-
tivation (46). Our results clearly suggest that the priming
effect ofGM-CSF on the respiratory burst in FMLP-stimulated
cells is due to the enhanced sustained formation of DRG in
these cells and the possible subsequent activation of the PKC
(49) . DRG and PdtOH, through DRG lipase (44) or specific
PdtOH phospholipase A2 (45), are both potential sources for
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